Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase&#xa0;2a Trial

Inflammatory Bowel Disease

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L, ASTRO Study Group

doi: 10.1016/S2468-1253(25)00322-X

Inflammatory Bowel Disease

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

J Gastroenterol Hepatol

Wei SC, Nakase H, Ye BD, Chao K, Wu HY, Eccleston J, Yao X, Palac H, Mohamed MF, Ponce-Bobadilla AV, Suravaram S, Barrachina EM, Hisamatsu T, Gao X

doi: 10.1111/jgh.70634

Inflammatory Bowel Disease

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Lancet Gastroenterol Hepatol

Reinisch W, Stepek D, Kempinski R, Danese S, Sands BE, Ratiu-Duma B, Singh R, Levine P, Barkay H, Gross N, Abrams K, Jairath V

doi: 10.1016/S2468-1253(26)00120-2

Inflammatory Bowel Disease

Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis

Inflamm Bowel Dis

Rubin DT, Danese S, Nakase H, Ungaro RC, Wolf DC, Alekseeva O, Petersen A, Liu Z, Mehra D, Jain A, Osterman MT, Krakovich A, Riolo JV, DeBoer E, Appio J, Sinh P, Cree BAC, Cohen JA, Irving P

doi: 10.1093/ibd/izaf319

Inflammatory Bowel Disease

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial

Clin Gastroenterol Hepatol

Danese S, Goetsch M, Peyrin-Biroulet L, Yarur AJ, Dubinsky M, Rubin DT, Feagan BG, D'Haens G, Baert F, Lazin K, Gu G, Yu J, Lawendy N, Zang C, Wang W, Menon S, Law EH, Modesto I, Wosik K, Sidhu S, Niezychowski W, Vermeire S

doi: 10.1016/j.cgh.2026.05.024

Inflammatory Bowel Disease

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Inflamm Bowel Dis

Turner D, Lomax KG, Veereman G, Griffiths AM, Kierkuś J, Kang B, Berezny K, Padgett L, Mao G, Zitser Y, Strauss RS, Verhoeven J, Adedokun OJ, Hyams JS

doi: 10.1093/ibd/izaf322

Inflammatory Bowel Disease

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Lancet Gastroenterol Hepatol

Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group

doi: 10.1016/S2468-1253(25)00198-0

Inflammatory Bowel Disease

Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study

J Crohns Colitis

D'Amico F, Fanizzi F, Dal Buono A, Gabbiadini R, Nardone OM, Zilli A, Allocca M, Lauriola GM, Jairath V, Peyrin-Biroulet L, Fiorino G, Castiglione F, Massimino L, Mastronardi M, Armuzzi A, Danese S

doi: 10.1093/ecco-jcc/jjag062

Inflammatory Bowel Disease

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial

Inflamm Bowel Dis

Afzali A, Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, Panés J, Van Rampelbergh R, Terry NA, Salese L, Vetter ML, Yee J, Corbett C, van Duijnhoven W, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI 1 investigators

doi: 10.1093/ibd/izag055

Gastroenterology

Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase 2a Trial

Related content

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial

Efficacy, Safety, and Pharmacokinetics of Golimumab in Children with Moderately-To-Severely Active Ulcerative Colitis: Results from the PURSUIT 2 Study

Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial